<p>TuHURA Biosciences（納斯達克：HURA - 獲取免費報告）預計將在 5 月 15 日（星期五）公佈其業績。分析師預計該公司本季度每股收益為（$0.12）。</p>
<p>獲取 <strong>TuHURA Biosciences</strong> 的提醒：</p>
<p>TuHURA Biosciences（納斯達克：HURA - 獲取免費報告）最近一次發佈季度財報是在 3 月 31 日（星期二）。該公司報告本季度每股收益為（$0.13），低於市場共識預期的（$0.12），差距為（$0.01）。分析師平均預計 TuHURA Biosciences 在當前財年每股收益為$0，在下一個財年每股收益也為$0。</p>
<h2>TuHURA Biosciences 股價下跌 5.5%</h2>
<p>TuHURA Biosciences 的股票在星期五開盤價為$2.40。該公司的市值為 1.5283 億美元，市盈率為-3.81，貝塔值為-0.01。TuHURA Biosciences 的 12 個月低點為$0.41，12 個月高點為$4.20。該股票的 50 日移動平均線為$2.05，200 日移動平均線為$1.60。</p>
<h2>分析師設定新目標價</h2>
<p>一些股票研究分析師最近對 HURA 股票發表了看法。Weiss Ratings 在 4 月 21 日（星期二）發佈的報告中重新給予 TuHURA Biosciences 股票&#34;賣出（e+）&#34;評級。花旗集團在 4 月 27 日（星期一）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;跑贏大盤&#34;評級。Citizens Jmp 在 4 月 27 日（星期一）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;市場跑贏&#34;評級，目標價為$9.00。HC Wainwright 在 2 月 3 日（星期二）重新給予&#34;買入&#34;評級，並設定目標價為$10.00。最後，Rodman &amp; Renshaw 在 4 月 15 日（星期三）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;買入&#34;評級。五位投資分析師對該股票給予買入評級，一位分析師給予賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為&#34;適度買入&#34;，平均目標價為$9.00。</p>
<p><strong>查看我們對 TuHURA Biosciences 的最新分析</strong></p>
<h2>對 TuHURA Biosciences 的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近增加或減少了對該公司的持股。Virtu Financial LLC 在第三季度購買了 TuHURA Biosciences 的新股份，價值$26,000。摩根大通在第二季度購買了 TuHURA Biosciences 的新頭寸，價值$27,000。Invesco Ltd.在第二季度購買了 TuHURA Biosciences 的新頭寸，價值約$30,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度收購了 TuHURA Biosciences 的新股份，價值$31,000。最後，美國銀行在第四季度購買了 TuHURA Biosciences 的新頭寸，價值$59,000。目前，機構投資者和對沖基金持有該股票的 0.62%。</p>
<h2>TuHURA Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>TuHURA Biosciences 是一家臨牀階段的生物技術公司，專注於利用高維蛋白質組學發現和開發新型治療藥物。公司的核心使命是將複雜的蛋白質特徵轉化為可操作的藥物靶點，涵蓋多種疾病領域。通過將蛋白質組數據與先進的計算分析相結合，TuHURA 旨在彌合分子疾病理解與首創療法開發之間的差距。</p>
<p>TuHURA 的方法的核心是其專有平台，該平台利用多重蛋白質分析生成豐富的疾病狀態表型圖。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 TuHURA Biosciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 TuHURA Biosciences 嗎？</h2>
<p>在你考慮 TuHURA Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 TuHURA Biosciences 並不在名單上。</p>
<p>雖然 TuHURA Biosciences 目前在分析師中獲得&#34;適度買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HURA

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

<p>TuHURA Biosciences (NASDAQ:HURA) 將於 5 月 15 日（星期五）公佈其財報，分析師預計每股虧損 0.12 美元。該公司之前報告的每股虧損為 0.13 美元，未能達到預期。目前，TuHURA 的股票交易價格為 2.40 美元，下跌 5.5%，市值為 1.5283 億美元。分析師的評級意見不一，普遍共識為 “適度買入”，平均目標價格為 9.00 美元。機構投資者最近增加了對該公司的持股，該公司專注於通過蛋白質組學開發新型治療藥物</p>

<p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) is projected to announce its resultson Friday, May 15th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.</p>
<div class="lb-trans"><p>TuHURA Biosciences（納斯達克：HURA - 獲取免費報告）預計將在 5 月 15 日（星期五）公佈其業績。分析師預計該公司本季度每股收益為（$0.12）。</p>
</div><p>Get <strong>TuHURA Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>TuHURA Biosciences</strong> 的提醒：</p>
</div><p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>TuHURA Biosciences（納斯達克：HURA - 獲取免費報告）最近一次發佈季度財報是在 3 月 31 日（星期二）。該公司報告本季度每股收益為（$0.13），低於市場共識預期的（$0.12），差距為（$0.01）。分析師平均預計 TuHURA Biosciences 在當前財年每股收益為$0，在下一個財年每股收益也為$0。</p>
</div><h2>TuHURA Biosciences Trading Down 5.5%</h2>
<div class="lb-trans"><h2>TuHURA Biosciences 股價下跌 5.5%</h2>
</div><p>TuHURA Biosciences stock opened at $2.40 on Friday. The company has a market capitalization of $152.83 million, a price-to-earnings ratio of -3.81 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20. The stock's 50 day moving average is $2.05 and its 200-day moving average is $1.60.</p>
<div class="lb-trans"><p>TuHURA Biosciences 的股票在星期五開盤價為$2.40。該公司的市值為 1.5283 億美元，市盈率為-3.81，貝塔值為-0.01。TuHURA Biosciences 的 12 個月低點為$0.41，12 個月高點為$4.20。該股票的 50 日移動平均線為$2.05，200 日移動平均線為$1.60。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of equities research analysts have recently weighed in on HURA shares. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an &#34;outperform&#34; rating on the stock. Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a &#34;market outperform&#34; rating and a $9.00 price objective for the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Rodman &amp; Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They issued a &#34;buy&#34; rating for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $9.00.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 HURA 股票發表了看法。Weiss Ratings 在 4 月 21 日（星期二）發佈的報告中重新給予 TuHURA Biosciences 股票&#34;賣出（e+）&#34;評級。花旗集團在 4 月 27 日（星期一）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;跑贏大盤&#34;評級。Citizens Jmp 在 4 月 27 日（星期一）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;市場跑贏&#34;評級，目標價為$9.00。HC Wainwright 在 2 月 3 日（星期二）重新給予&#34;買入&#34;評級，並設定目標價為$10.00。最後，Rodman &amp; Renshaw 在 4 月 15 日（星期三）的研究報告中開始覆蓋 TuHURA Biosciences 股票，並給予&#34;買入&#34;評級。五位投資分析師對該股票給予買入評級，一位分析師給予賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為&#34;適度買入&#34;，平均目標價為$9.00。</p>
</div><p><strong>Check Out Our Latest Analysis on TuHURA Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我們對 TuHURA Biosciences 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On TuHURA Biosciences</h2>
<div class="lb-trans"><h2>對 TuHURA Biosciences 的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase &amp; Co. bought a new position in TuHURA Biosciences during the 2nd quarter worth $27,000. Invesco Ltd. bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $31,000. Finally, Bank of America Corp DE bought a new position in TuHURA Biosciences during the fourth quarter worth $59,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了對該公司的持股。Virtu Financial LLC 在第三季度購買了 TuHURA Biosciences 的新股份，價值$26,000。摩根大通在第二季度購買了 TuHURA Biosciences 的新頭寸，價值$27,000。Invesco Ltd.在第二季度購買了 TuHURA Biosciences 的新頭寸，價值約$30,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度收購了 TuHURA Biosciences 的新股份，價值$31,000。最後，美國銀行在第四季度購買了 TuHURA Biosciences 的新頭寸，價值$59,000。目前，機構投資者和對沖基金持有該股票的 0.62%。</p>
</div><h2>TuHURA Biosciences Company Profile</h2>
<div class="lb-trans"><h2>TuHURA Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.</p>
<div class="lb-trans"><p>TuHURA Biosciences 是一家臨牀階段的生物技術公司，專注於利用高維蛋白質組學發現和開發新型治療藥物。公司的核心使命是將複雜的蛋白質特徵轉化為可操作的藥物靶點，涵蓋多種疾病領域。通過將蛋白質組數據與先進的計算分析相結合，TuHURA 旨在彌合分子疾病理解與首創療法開發之間的差距。</p>
</div><p>At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.</p>
<div class="lb-trans"><p>TuHURA 的方法的核心是其專有平台，該平台利用多重蛋白質分析生成豐富的疾病狀態表型圖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than TuHURA Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 TuHURA Biosciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=HURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TuHURA Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 TuHURA Biosciences 嗎？</h2>
</div><p>Before you consider TuHURA Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 TuHURA Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 TuHURA Biosciences 並不在名單上。</p>
</div><p>While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TuHURA Biosciences 目前在分析師中獲得&#34;適度買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

TuHURA Biosciences (HURA) 預計將在週五發佈財報